InvestorsHub Logo
Followers 49
Posts 9831
Boards Moderated 1
Alias Born 01/31/2008

Re: Talon38 post# 111639

Tuesday, 07/18/2017 4:21:19 PM

Tuesday, July 18, 2017 4:21:19 PM

Post# of 474044
Agree, but dont think they are just sitting on their hands. They have been talking to the FDA all along about what they want to see in a trial to give accelerated approval, I would surmise. That is because there were already special procedures at the FDA to expedite any alz drug, which is a top national priority.

As I said a couple months back, Missling has made it very clear that you find out if the drug works in much cheaper P2, and P3 is the optimized trial to get the FDA signoff. For alz, the possibility of getting accelerated approval has been there all along, which is why we continued to keep extending the P2 trials so we would have an even better case for accelerated approval by showing long term safety and effectiveness.

So the new proposals by the Trump FDA are packaging, but the basic were there already for alz. That has been Misslings plan all along.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News